| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC74245 | STK018404 | STK018404 is a small molecule inhibitor of RNA-binding protein human antigen R (HuR), decreases the binding of HuR to its target RNA motif. |
|
| DC74246 | AA132 | AA132 (AA-132) is a small molecule activator of UPR signaling, covalently modifies a subset of ER protein disulfide isomerases (PDIs), activates global UPR signaling through a mechanism analogous to that of AA147. |
|
| DC74247 | AG-946 Featured | AG-946 (AG946) is a potent, allosteric activator of wild-type and mutant RBC-specific form of pyruvate kinase (PKR) with AC50 of 5 nM for human wild-type PK, 4.3 nM and 6.9 nM for mutated K410E and R510Q PK proteins, resepctively. |
|
| DC74248 | HA344 | HA344 (HA 344) is a dual covalent inhibitor of pyruvate kinase M2 (PKM2) and inosine monophosphate dehydrogenase (IMPDH), efficiently inhibits cutaneous metastatic melanoma (CMM). |
|
| DC74249 | TAS0612 | TAS0612 (TAS-0612) is an orally bioavailable multikinase inhibitor of AKT, p70S6K, and p90RSK, inhibits Y-box-binding protein (YBX1) phosphorylation. |
|
| DC74250 | TCMDC-136364 | TCMDC-136364 (AKT Kinase Inhibitor) is an Akt kinase inhibitor, selectively inhibits Akt in proliferating cells expressing Trop-2, also potently inhibits P. falciparum multidrug resistant strain Dd2. |
|
| DC74251 | BI-9774 Featured | BI-9774 (BI 9774) is a potent pan-AMPK activator with EC50 of 64 nM in an ADP-Glo kinase assay with human AMPK (α1β1γ1) and EC50 of 8 nM in a cellular GLUT4 translocation assay. |
|
| DC74252 | KI-301670 | KI-301670 is a novel potent, specific NUAK1 inhibitor, disturbs NUAK1 signaling by targeting its ATP binding site, effectively inhibits the PI3K/AKT pathway in pancreatic cancer cells. |
|
| DC74253 | MSG011 | MSG011 is a potent, pan AMPK isoform activator with EC50 of 140.4 nM, 248.9 nM, 553.4 nM, and 472.9 nM for α1β1γ1, α1β2γ1, α2β1γ1, and α2β2γ1, respectively. |
|
| DC74254 | PXL770 | PXL770 is a novel orally bioavailable, small-molecule direct AMPK activator with EC50 of 16.2, 42.1 and 64 nM for α1β1γ1, α1β1γ2 and α1β1γ3, directly increases AMPK activity by both allosteric activation and protection from dephosphorylation. |
|
| DC74255 | PXL770 monohydrate potassium salt | PXL770 is a novel orally bioavailable, small-molecule direct AMPK activator with EC50 of 16.2, 42.1 and 64 nM for α1β1γ1, α1β1γ2 and α1β1γ3, directly increases AMPK activity by both allosteric activation and protection from dephosphorylation. |
|
| DC74256 | RX-375 | RX-375 (RX375) is an indirect small-molecule activator of AMPK by directly binds to Prohibitins (PHB1 and PHB2), induces dissociation of AMPK-PHBs complex. |
|
| DC74257 | ZLN-024 hydrochloride | ZLN-024 hydrochloride is a potent, allosteric AMPK activator that has no effect on mitochondrial function or the ADP/ATP ratio, directly activate recombinant AMPK α1β1γ1 and its homologue α2β1γ1 with EC50 of 0.42 uM and 0.95 uM, respectively. |
|
| DC74258 | NV-5297 | NV-5297 (NV5297) is a novel small molecule mTORC1 pathway activator, modulates the Sestrin2-Gator2 interaction and activates the mTORC1 pathway in vitro and in vivo. |
|
| DC74259 | CU05-1189 | CU05-1189 is a non-peptide, allosteric inhibitor of the pleckstrin homology (PH) domain of PDK1, specifically inhibits Akt signaling pathway. |
|
| DC74260 | cyclo-CRVLIR Featured | cyclo-CRVLIR is a cyclic peptide that binds selectively to p110α RAS binding domain (p110α-RBD) with ITC Kd of 3 uM, blocks p110α/RAS interaction in vitro and KRAS cancer cell lines. |
|
| DC74261 | HM5023507 | HM5023507 is a potemt, selective, orally active dual PI3Kδ/γ inhibitor with IC50 of 4 nM and 5 nM for p110γ and p110δ, respectively. |
|
| DC74262 | I-229 | I-229 is a potent and selective inhibitor of Vps34. |
|
| DC74263 | LL-00071210 | LL-00071210 is a potent, selective, orally bioavailable PI3Kδ inhibitor with IC50 values of 24.6 nM and 9.4 nM in biochemical and cellular assays, respectively. |
|
| DC74264 | LL-00084282 | LL-00084282 is a potent, selective and efficacious dual PI3Kδγ inhibitor with IC50 of 16.26 and 17.45 nM for PI3Kδ and PI3Kγ, respectively. |
|
| DC74265 | LP-182 | LP-182 (LP182) is a potent, selective and orally bioavailable multi-functional kinase inhibitor, specifically targets PI3K and MAPK signaling pathways. |
|
| DC74266 | PF-06862309 | PF-06862309 (PF-06843195 phosphate ester prodrug) is the in vivo-active, phosphate ester prodrug of PF-06843195, a potent selective PI3Kα inhibitor with Kd of <18 pM. |
|
| DC74267 | PITCOIN2 | PITCOIN2 (LU-06-006) is a potent selective PI3KC2α inhibitor with IC50 of 126 nM, has selectivity against PI3KC2γ but shows micromolar activity on PI3KC2β. |
|
| DC74268 | PITCOIN3 | PITCOIN3 is a potent, highly selective, cell-permeable inhibitor of PI3KC2α catalytic activity with IC50 of 126 nM. |
|
| DC74269 | TGX286 | TGX286 is a potent, selective p110β inhibitor with IC50 of 7, 17 and 13 nM for p110β WT, p110β D862Q, and p110β E858H, respectively, >100-fold selectivity over p110α. |
|
| DC74270 | GSK-3923868 | GSK-3923868 (PI4KB inhibitor 30) is a potent, selective, slow-dissociating PI4KB (PI4kIII-beta) inhibitor with pKi of 9.8, >1000-fold selectivity over PI4KA, inhibits HRV viral replication in COPD BECs. |
|
| DC74271 | HZX-02-059 | HZX-02-059 is a PIKfyve and tubulin dual-target inhibitor with high affinity for PIKfyve (Kd=10.4 nM), HZX-02-059 is a potent methuosis inducer, shows both in vitro and in vivo anti-tumor activity against TNBC. |
|
| DC74272 | BAY-728 | BAY-728 (NAY728) is a less potent enantiomer and negative control compound of BAY-805. |
|
| DC74273 | BK50118-C | BK50118-C is a potent small molecule inhibitor of ubiquitin-specific protease-13 (USP13) with IC50 of 0.42 nM. |
|
| DC74274 | BML-260 | BML-260 (BML260) is a potent inhibitor of dual-specific phosphatase JSP-1 (JNK Stimulatory Phosphatase-1, DUSP22) and stimulator of uncoupling protein 1 (UCP-1) expression in adipocytes. |
|
